Mark Lackner

Executive

Zentalis Pharmaceuticals, Inc.

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 1 saleFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (14 ops.)

€230k

Latest filing published 05 Feb 2025 for Zentalis Pharmaceuticals, Inc..

Filing timeline

BuySale

Mark Lackner

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Mark Lackner: trading record in brief

This profile gathers the share dealings of Mark Lackner across 2 companies, led by IDEAYA Biosciences, Inc. and Zentalis Pharmaceuticals, Inc. In total, 25 filings cover trades dated from 2 June 2020 to 3 February 2025.

The open-market record consists of 14 sales worth €230k, with no purchase. Besides market trades, the filings include 3 share grants and 8 option exercises. Since January 2025: no purchases and 2 sales on the market.

Most recently, on 5 February 2025, the filings show an open-market sale worth €24k in Zentalis Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.